Shandong, Shanxi and other places have clarified the implementation time of the seventh batch of national centralized procurement of drugs

【Pharmaceutical Network Industry News】 The results of the seventh batch of national centralized procurement drugs were announced
on July 18.
It is reported that a number of places have recently issued documents clarifying the landing time and specific policies
of the seventh batch of national centralized procurement drugs.
For example, on October 28, the Shandong Provincial Medical Insurance Bureau issued the "Notice on Implementing the Selection Results of the Seventh Batch of Centralized Procurement of Drugs by the State Organization", saying that since November 18, the whole province of Shandong has participated in the seventh batch of public medical institutions (including military medical institutions stationed in Lu, the same below) and medical insurance designated social medical institutions (hereinafter referred to as "medical institutions") to implement the results of the seventh batch of national procurement and sell the selected drugs
to patients 。 On the same day, the Shanxi Provincial Medical Security Bureau also issued the Notice on Fully Implementing the Selection Results of the Seventh Batch of State-Organized Centralized Drug Procurement, saying that from November 20, all public medical institutions in Shanxi Province will fully implement the results of the seventh batch of state-organized centralized drug procurement
.
In addition, Henan, Qinghai, Zhejiang, Liaoning, Shanxi, Shanghai and Hainan have previously issued documents clarifying the landing time and specific policies
of the seventh batch of national centralized procurement drugs.
For example, Henan, Qinghai and other places are scheduled to implement the results of the seventh batch of national centralized procurement drugs from November 1, and Liaoning Province is scheduled to start implementing the seventh batch of state-organized drugs (Liaoning) on November 20; Zhejiang Province will start implementing the results
of the seventh batch of national procurement on November 10, 2022.
The seventh batch of centralized procurement of drugs organized by the state, a total of 60 kinds of drugs were successfully purchased, with an average price reduction of 48%, involving 31 treatment categories, including hypertension, diabetes, anti-infection, digestive tract diseases and other common diseases, chronic diseases, as well as lung
cancer, liver cancer, kidney cancer, bowel cancer and other major diseases.
Among them, the sustained-release dosage form was included in the field of lowering blood pressure, the price of nifedipine controlled-release tablets was reduced by 58%, and the price of metoprolol sustained-release tablets was reduced by 53%, and the drug burden of hypertensive patients was significantly reduced
.
The antiviral drug oseltamivir dropped from an average of 4.
5 yuan to 1 yuan
per tablet.
In terms of drugs for major diseases, taking lenvatinib capsules, the first-line targeted drug for liver cancer, as an example, each capsule has dropped from an average of 108 yuan to an average of 18 yuan, and a treatment cycle can save 8100 yuan
.
Centralized procurement has effectively squeezed the inflated prices of related pharmaceutical consumables, promoted the reduction of overall drug consumption prices, gradually reduced the burden of medical expenses on the masses, made clinical diagnosis and treatment behavior more standardized, continuously increased the utilization rate of medical insurance funds, and effectively purified
the environment for pharmaceutical purchase and sales.
The reform of medical care, medical insurance and medicine linkage has achieved remarkable results, the public's sense of gain has been greatly improved, and the positive effect of multiple parties has gradually emerged
.
It is reported that after the implementation of this centralized procurement of drugs, the number of national, provincial and inter-provincial alliance centralized procurement drugs implemented by Shanxi Province will reach 432, and 75 kinds of consumables (including 17 high-value and 58 low-value), with an average reduction of more than 50%, which can save related costs by 5 billion yuan
a year.
In order to better ensure the stable supply of centralized procurement drugs, the seventh batch of centralized procurement for the first time clearly introduced the "backup supply enterprise" mechanism in the procurement documents, and explored the realization of "one province and two supply", each province not only has 1 selected enterprise, that is, the main supply enterprise, but also has 1 backup supply enterprise
.
"The backup supply mechanism has improved the problem of some of
the previous centralized drug supply cuts.
For example, Shandong Province clarified in the notice the "timetable" for the landing of the results of the seventh batch of national centralized procurement drugs: before November 13, 2022, the main supplier enterprises and the backup supply enterprises will respectively hang the selected drugs and spare drugs on the provincial centralized procurement platform for drugs and equipment according to the selected price, so that medical institutions can purchase an appropriate amount of selected drugs for
stocking.
Before November 10, 2022, the main supplier enterprises and the backup supply enterprises will select distribution enterprises through the provincial centralized procurement platform for drugs and equipment to complete the establishment of
distribution relationships.
In accordance with the principle of localized management, before November 10, 2022, the medical insurance departments of each municipality have selected and determined medical institutions as representatives, and signed purchase and sales agreements with the main supplier enterprises through the provincial centralized procurement platform for drugs and devices, and the purchase and sales agreements are signed once a year, and the procurement cycle of the first year is: November 13, 2022 - November 30, 2023
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.